|
||||||||||||||||||||||
|
|
Phase II-III Chemotherapy with Hexamethylmelamine and L-Phenylalanine Mustard for Stage III and IV Ovarian Carcinoma
Basic Trial Information
Objectives I. Assess the Induction efficacy of combination chemotherapy with hexamethylmelamine and L-PAM in patients with F.I.G.O. Stage III or IV ovarian carcinoma who have not achieved PR or CR on an adriamycin plus cyclophosphamide regimen (ADR/CTX), or who are not suitable candidates for adriamycin therapy. II. Compare results of this study with historical controls. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with measurable lesions of ovarian carcinoma FIGO Stage III or IV with acceptable hematological status. Expected Enrollment Protocol closed 11/76. Outline Nonrandomized study. 2-Drug Combination Chemotherapy. Phenylalanine mustard, L-PAM, NSC-8806; Hexamethylmelamine, HMM, NSC-13875. Trial Lead Organizations Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |